News

Public · Published

Healthcare could be the next big AI winner: Becci McKinley-Rowe

BlackRock Fundamental Equities' quantitative team analysed more than a thousand public company earnings reports and found a growing share of US-market sectors reporting tangible financial gains from AI. The article says healthcare may be especially well placed, citing its extensive private drug-development data and opportunities to reduce research costs and speed drug development.

Published:

Updated:

What happened

BlackRock Fundamental Equities’ quantitative team analysed more than a thousand public company earnings reports and found a growing share of US-market sectors reporting tangible financial gains from AI. The article says healthcare may be especially well placed, citing its extensive private drug-development data and opportunities to reduce research costs and speed drug development.

Confirmed

Global impact / market context

If healthcare companies use AI to learn from their private drug-development records, they could potentially identify promising medicines more efficiently. Shorter or less costly research could reduce spending and bring revenue from successful drugs sooner, but the article does not establish that these gains have broadly occurred.

Analyst inference

The article contrasts an earlier AI wave that benefited semiconductor and infrastructure suppliers with a possible next wave benefiting companies that adopt AI. It also notes adoption remains uneven: only 30% of technology companies say AI has boosted their bottom line.

Confirmed

What to watch

  1. Watch for healthcare companies to report measurable reductions in research and development costs or faster drug development, since these would show AI is translating into financial results. Analyst inference
  2. Look for evidence that companies can use private drug-development records to train AI systems; the article says some hold more than a century of proprietary data. Confirmed
  3. Track whether reported AI gains spread beyond current leaders, because broader adoption could shift investor attention from equipment suppliers toward companies using AI in healthcare. Analyst inference

Evidence

  • Original source link unavailable